{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:55Z","timestamp":1791216775404,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[1994,8,1]],"date-time":"1994-08-01T00:00:00Z","timestamp":775699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Agents and Actions"],"published-print":{"date-parts":[[1994,8]]},"DOI":"10.1007\/bf02014300","type":"journal-article","created":{"date-parts":[[2005,8,5]],"date-time":"2005-08-05T08:23:48Z","timestamp":1123230228000},"page":"50-55","source":"Crossref","is-referenced-by-count":15,"title":["Antirheumatic drug profiles evaluated in the adjuvant arthritis of rats by multiparameter analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"P.","family":"Theisen-Popp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"M\u00fcller-Peddinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF02014300_CR1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1172\/JCI111193","volume":"73","author":"J. Holoshitz","year":"1984","unstructured":"J. Holoshitz, A. Matitiau and I. R. Cohen,Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. J. Clin. Invest.73, 211\u2013215 (1984).","journal-title":"J. Clin. Invest."},{"key":"BF02014300_CR2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0163-7258(83)90062-1","volume":"21","author":"M. E. J. Billingham","year":"1983","unstructured":"M. E. J. Billingham,Models of arthritis and the search for anti-arthritic drugs. Pharmacol. Ther.21, 389\u2013428 (1983).","journal-title":"Pharmacol. Ther."},{"key":"BF02014300_CR3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0192-0561(92)90117-4","volume":"14","author":"P. Theisen-Popp","year":"1992","unstructured":"P. Theisen-Popp, H. Pape and R. M\u00fcller-Peddinghaus,Interleukin-6 (IL-6) in adjuvant arthritis of rats and its pharmacological modulation. Int. J. Immunopharmacol.14, 565\u2013571 (1992).","journal-title":"Int. J. Immunopharmacol."},{"key":"BF02014300_CR4","first-page":"103","volume":"236","author":"M. J. Dimartino","year":"1986","unstructured":"M. J. Dimartino, J. C. Lee, A. M. Badger, K. A. Muirhead, C. K. Mirabelli and N. Hanna, Antiarthritic and immunoregulatory activity of spirogermanium. J. Pharmacol. Exp. Ther.236, 103\u2013110 (1986).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF02014300_CR5","first-page":"180","volume":"254","author":"K. R. Gans","year":"1990","unstructured":"K. R. Gans, W. Galbraith, R. J. Roman, S. B. Haber, J. S. Kerr, W. K. Schmidt, C. Smith, W. E. Hewes and N. R. Ackerman, Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J. Pharmacol. Exp. Ther.254, 180\u2013187 (1990).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF02014300_CR6","first-page":"229","volume-title":"Therapeutic Approaches to Inflammatory diseases","author":"I. G. Otterness","year":"1989","unstructured":"I. G. Otterness, T. J. Carty and L. D. Loose,Tenidap: A new drug for arthritis. InTherapeutic Approaches to Inflammatory diseases. (Eds. A. J. Lewis, N. S. Doherty and N. R. Ackerman) pp. 229\u2013241, Elsevier, Amsterdam 1989."},{"key":"BF02014300_CR7","first-page":"505","volume":"18","author":"I. G. Otterness","year":"1991","unstructured":"I. G. Otterness, P. P. Pazoles, P. F. Moore and M. B. Pepys,C-reactive protein as an index of disease activity. Comparison of tenidap, cyclophosphamide and dexamethasone in rat adjuvant arthritis. J. Rheumatol.18, 505\u2013511 (1991).","journal-title":"J. Rheumatol."},{"key":"BF02014300_CR8","first-page":"579A","volume":"38","author":"L. D. Loose","year":"1990","unstructured":"L. D. Loose, B. H. Littman and J. D. Sipe,Modulation of acute phase proteins by tenidap, a new anti-inflammatory, antirheumatic drug. Clin. Res.38, 579A (1990).","journal-title":"Clin. Res."},{"issue":"4, Suppl.","key":"BF02014300_CR9","first-page":"A87","volume":"31","author":"P. Katz","year":"1988","unstructured":"P. Katz, A. P. Borger and L. D. Loose,Evaluation of CP-66, 248 [5-chloro-2,3-dihydro-2-oxo-3-(2-thienyl-carbonyl)-indole-1-carboxamide] in rheumatoid arthritis (RA). Arthritis Rheum.31 (4, Suppl.), A87 (1988).","journal-title":"Arthritis Rheum."},{"key":"BF02014300_CR10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4049\/jimmunol.148.2.480","volume":"148","author":"J. D. Sipe","year":"1992","unstructured":"J. D. Sipe, L. M. Bartle and L. D. Loose,Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. J. Immunol.148, 480\u2013484 (1992).","journal-title":"J. Immunol."},{"key":"BF02014300_CR11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0162-3109(88)90024-0","volume":"15","author":"K. M. Connolly","year":"1988","unstructured":"K. M. Connolly, V. J. Stecher, T. Labrie and C. Fluno,Modulation of the acute phase response and in vitro measurement of interleukin-1 activity following administration of dexamethasone to adjuvant-arthritic rats. Immunopharmacology15, 133\u2013142 (1988).","journal-title":"Immunopharmacology"},{"key":"BF02014300_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(93)80952-Q","volume":"328","author":"L. Fesus","year":"1993","unstructured":"L. Fesus,Biochemical events in naturally occurring forms of cell death. FEBS Lett.328, 1\u20135 (1993).","journal-title":"FEBS Lett."},{"key":"BF02014300_CR13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jps.2600770915","volume":"77","author":"I. Otterness","year":"1988","unstructured":"I. Otterness and D. Gans,Nonsteroidal anti-inflammatory drugs: An analysis of the relationship between laboratory animal and clinical doses, including species scaling. Pharmacol. Sci.77, 790\u2013795 (1988).","journal-title":"Pharmacol. Sci."},{"key":"BF02014300_CR14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0167-5699(90)90173-7","volume":"11","author":"T. Hirano","year":"1990","unstructured":"T. Hirano, S. Akira, T. Taga and T. Kishimoto,Biological and clinical aspects of interleukin 6: Immunol. Today11, 443\u2013449 (1990).","journal-title":"Immunol. Today"},{"key":"BF02014300_CR15","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.4049\/jimmunol.151.7.3682","volume":"151","author":"D. E. Hatzigeorgiou","year":"1993","unstructured":"D. E. Hatzigeorgiou, S. He, J. Sobel, K. H. Grabstein, A. Hafner and J. L. Ho,IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J. Immunol.151, 3682\u20133692 (1993).","journal-title":"J. Immunol."},{"key":"BF02014300_CR16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-3-0348-9146-2_3","volume":"33","author":"A. C. Allison","year":"1989","unstructured":"A. C. Allison and S. W. Lee,The mode of action of anti-rheumatic drugs. 1. Anti-inflammatory and immunosuppressive effects of glucocorticoids. Progr. Drug. Res.33, 63\u201381 (1989).","journal-title":"Progr. Drug. Res."},{"key":"BF02014300_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/clin.1993.1171","volume":"69","author":"L. M. Breuninger","year":"1993","unstructured":"L. M. Breuninger, W. L. Dempsey, J. Uhl and D. M. Murasko,Hydrocortisone regulation of interleukin-6 protein production by a purified population of human peripheral blood monocytes. Clin. Immunol. Immunopathol.69, 205\u2013214 (1993).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BF02014300_CR18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01972366","volume":"15","author":"A. W. Thomson","year":"1984","unstructured":"A. W. Thomson, P. H. Whiting and J. G. Simpson,Cyclosporine: Immunology, toxicity and pharmacology in experimental animals. Agents and Actions15, 306\u2013327 (1984).","journal-title":"Agents and Actions"},{"key":"BF02014300_CR19","series-title":"Adv. Inflamm. Res.","first-page":"277","volume-title":"Therapeutic control of inflammatory diseases new approaches to antirheumatic drugs","author":"J. F. Borel","year":"1986","unstructured":"J. F. Borel, H. U. Gubler, P. C. Hiestand and R. M. Wenger,Immunopharmacological properties of cyclosporine (Sandimmune\u00ae) and (Val 2)-dihydrocyclosporine and their prospect in chronic inflammation. InTherapeutic control of inflammatory diseases new approaches to antirheumatic drugs. (Eds. I. Otterness, A. Lewis and R. Capetola) Raven Press, New York; Adv. Inflamm. Res.11, 277\u2013291 (1986)."},{"key":"BF02014300_CR20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0192-0561(88)90025-2","volume":"10","author":"K. M. Connolly","year":"1988","unstructured":"K. M. Connolly, V. J. Stecher, E. Danis, D. J. Pruden and T. Labrie,Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int. J. Immunopharmacol.10, 717\u2013728 (1988).","journal-title":"Int. J. Immunopharmacol."},{"key":"BF02014300_CR21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/art.1780330214","volume":"33","author":"E. Pozo del","year":"1990","unstructured":"E. del Pozo, M. Graeber, P. Elford and T. Payne,Regression of bone and cartilage loss in adjuvant arthritic rats after treatment with cyclosporin A. Arth. Rheum.33, 247\u2013252 (1990).","journal-title":"Arth. Rheum."},{"key":"BF02014300_CR22","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","volume":"45","author":"D. Faulds","year":"1993","unstructured":"D. Faulds, K. L. Goa and P. Benfield,Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs45, 953\u20131040 (1993).","journal-title":"Drugs"}],"container-title":["Agents and Actions"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02014300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02014300\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02014300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T01:26:48Z","timestamp":1683163608000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02014300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,8]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[1994,8]]}},"alternative-id":["BF02014300"],"URL":"https:\/\/doi.org\/10.1007\/bf02014300","relation":{},"ISSN":["0065-4299","1420-908X"],"issn-type":[{"value":"0065-4299","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,8]]}}}